Disclosed is the use of an Ep1 antagonist compound of formula (I) in the manufacture of a medicament for prevention, treatment and/or symptom improvement of dysuria, wherein the substituents are as described within the specification . Examples of compounds of formula (I) include: 3-methyl-4-[6-[N-isobutyl-N-(2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid； and 4-[6-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid.
